Drug intelligence / Profile preview

adebrelimab + docetaxel + oxaliplatin + S-1

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
Administration: Intravenous, Oral

Overview

Adebrelimab + docetaxel + oxaliplatin + S-1 (DOS) is a combination chemo-immunotherapy regimen being evaluated for the neoadjuvant treatment of resectable locally advanced gastric cancer. Adebrelimab is a humanized IgG4 monoclonal antibody that targets programmed death-ligand 1 (PD-L1), preventing its interaction with PD-1 and B7.1 receptors to restore anti-tumor T-cell activity. The DOS regimen consists of docetaxel (a microtubule stabilizer), oxaliplatin (a platinum-based DNA cross-linking agent), and S-1 (an oral fluoropyrimidine combination of tegafur, gimeracil, and oteracil). This combination is currently being investigated in a Phase II trial sponsored by Tang-Du Hospital to improve pathological complete response (pCR) rates and surgical outcomes in patients with advanced gastric cancer.

Brand names: Adshirda
Other names: adebrelimab + DOSSHR-1316 + DOS

Targets

TUBB (Tubulin (alpha and beta subunits))DNATS (Thymidylate synthase)CD274 (Programmed cell death protein 1 ligand 1)

Beyond the preview

Go deeper on adebrelimab + docetaxel + oxaliplatin + S-1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on adebrelimab + docetaxel + oxaliplatin + S-1.

Explore the full profile